Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary and Q&A session reveal a generally positive outlook. The company has raised earnings guidance, expects occupancy growth, and plans asset sales for capital optimization. The Q&A highlighted strong leasing activity, positive AI impact, and robust demand for key projects. Management's strategic focus on occupancy gains and development partnerships, along with a raised FFO guidance, suggests optimism. Despite some vague responses, the overall sentiment is positive, likely leading to a stock price increase in the 2% to 8% range over the next two weeks.
Leasing Activity BXP completed over 1.8 million square feet of leasing for Q4 2025 and over 5.5 million square feet for the full year 2025, exceeding goals. This was driven by client growth, return-to-office mandates, and demand from AI companies.
Asset Sales BXP closed the sale of 12 assets for total net proceeds of over $1 billion in 2025, including $850 million in 2025 and $180 million in January 2026. This included land, residential, and office assets, with reasons including portfolio optimization and high cap rates.
Development Pipeline BXP has 8 projects underway, totaling 3.5 million square feet and $3.7 billion in investment. This includes 290 Binney Street, which is 100% leased to AstraZeneca and expected to deliver in mid-2026.
Occupancy BXP's in-service occupancy was 86.7% at the end of 2025, with expectations to improve to 89% by the end of 2026. This is supported by 1.243 million square feet of executed leases yet to commence.
Same-Property NOI Growth Same-property NOI growth for 2026 is projected at 1.25% to 2.25%, driven by higher occupancy and leasing activity.
Asset Dispositions BXP executed $1.1 billion in asset sales in 2025 and plans an additional $360 million in 2026. Proceeds are used to reduce debt and fund developments.
FFO (Funds From Operations) BXP reported FFO of $6.85 per share for 2025 and projects $6.88 to $7.04 per share for 2026, reflecting growth from higher occupancy, development contributions, and lower interest expenses.
G&A Expense G&A expense for Q4 2025 was $3.5 million higher than projected, due to increased compensation and legal expenses. For 2026, G&A is expected to increase by $13 million to $20 million, partly due to a new stock-based compensation plan.
Leasing Activity: Completed over 1.8 million square feet of leasing in Q4 and over 5.5 million square feet for the full year 2025, surpassing goals. Forecast occupancy gains have commenced.
New Developments: Launched new developments at 343 Madison Avenue in New York City and 725 12th Street in Washington, D.C. Plan to launch construction of 2100 M Street in 2028.
Residential Projects: Progressed on residential entitlement work, including plans for 385 units in Santa Monica and 100 townhomes in Weston, Massachusetts.
Premier Workplace Segment: Continued strong demand with direct vacancy at 11.6%, significantly lower than the broader market. Asking rents command a premium of over 50%.
AI Companies: Accelerating demand from AI companies, particularly in the Bay Area and New York City.
Asset Sales: Closed the sale of 12 assets for over $1 billion in net proceeds. Additional sales of 8 assets with estimated proceeds of $230 million planned for 2026.
Debt Reduction: Proceeds from asset sales used to reduce debt, including a $1 billion bond redemption in February.
Portfolio Optimization: Reallocating capital to premier workplace assets in CBD locations and selling suburban office and land assets.
Life Science Focus: Exited the Life Science business on the West Coast but remain committed to the sector in the Boston region.
Leasing Activity: Concerns about the impact of AI on job growth and leasing activity, though not currently supported by client actions, could pose a risk if realized. Additionally, the reliance on corporate return-to-office mandates for leasing growth may face resistance or delays.
Asset Sales and Portfolio Optimization: The company’s plan to sell $1.9 billion in assets by 2028, while progressing, could face challenges in achieving targeted valuations, especially in weaker markets like suburban locations or areas with high vacancy rates.
Development Projects: The long timelines for development projects, such as 343 Madison Avenue and 2100 M Street, which are expected to deliver returns years into the future, pose risks related to market conditions, construction costs, and financing availability over time.
Market Conditions: High vacancy rates in certain markets, such as South San Francisco for life sciences, and declining rents in some regions like the West Coast, could negatively impact revenue and leasing activity.
Debt and Financing: The company’s reliance on refinancing and construction loans for projects like 343 Madison Avenue introduces risks related to interest rate fluctuations and lender availability.
Operational Costs: Higher-than-expected G&A expenses and noncash reserves for accrued rental income, as seen in Q4 2025, could continue to pressure financial performance.
Regulatory and Entitlement Risks: The company’s strategy to redevelop suburban office buildings into residential units depends on obtaining zoning approvals and entitlements, which could face delays or denials.
Leasing and Occupancy Growth: BXP expects a 4% occupancy gain over the next two years, supported by strong leasing activity in 2025 and positive market trends. The company forecasts completing 4 million square feet of leasing in 2026, with occupancy projected to improve to 89% by the end of 2026.
Revenue and NOI Growth: Same-property NOI growth is projected between 1.25% and 2.25% for 2026, driven by higher occupancy and leasing activity. Incremental NOI from developments is expected to add $44 million to $52 million in 2026.
Development Projects: BXP plans to deliver 290 Binney Street, a 573,000 square foot life science project, in mid-2026, which is 100% leased. The company is also advancing other developments, including 343 Madison Avenue in New York City, with construction financing and equity partnerships expected in 2026.
Asset Sales and Portfolio Optimization: BXP aims to sell $360 million worth of assets in 2026, generating $230 million in net proceeds. The company is reallocating capital to premier workplace assets in CBD locations and removing suburban office buildings for redevelopment into residential projects.
Debt and Interest Expense: Net interest expense is expected to decrease by $38 million to $48 million in 2026 due to asset sales and debt reduction. The company plans to refinance a $1 billion bond maturing in October 2026 at an estimated rate of 5.5% to 5.75%.
FFO Guidance: BXP projects 2026 FFO in the range of $6.88 to $7.04 per share, representing an increase of $0.11 per share from 2025. Quarterly FFO run rates are expected to improve consistently throughout 2026.
The selected topic was not discussed during the call.
The earnings call summary and Q&A session reveal a generally positive outlook. The company has raised earnings guidance, expects occupancy growth, and plans asset sales for capital optimization. The Q&A highlighted strong leasing activity, positive AI impact, and robust demand for key projects. Management's strategic focus on occupancy gains and development partnerships, along with a raised FFO guidance, suggests optimism. Despite some vague responses, the overall sentiment is positive, likely leading to a stock price increase in the 2% to 8% range over the next two weeks.
The earnings call highlights increased earnings guidance, strong leasing activity, and strategic asset sales, which are positive indicators. Despite some uncertainties in smaller markets and the San Francisco recovery, the company is confident in occupancy growth and has a strategic approach to asset management. The Q&A session reinforced positive sentiments, with management expressing confidence in occupancy growth and strategic asset sales, despite some vague responses. Overall, the company's strategic initiatives and market confidence suggest a positive stock price movement.
The company shows strong market share growth, deposit growth, and sustainable profitability. Despite some management opacity, the overall tone is optimistic with strong financial metrics and strategic growth plans. The Q&A section highlights positive sentiment towards deposit growth and profitability, indicating a positive stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.